Capricor Therapeutics, Inc.
CAPR
$6.60
-$0.50-7.04%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 11.13M | 2.26M | 3.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 11.13M | 2.26M | 3.97M |
| Cost of Revenue | 22.05M | 18.92M | 14.55M | 11.81M | 12.50M |
| Gross Profit | -22.05M | -18.92M | -3.42M | -9.55M | -8.53M |
| SG&A Expenses | 5.67M | 6.07M | 4.27M | 3.46M | 3.06M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 27.72M | 24.98M | 18.83M | 15.27M | 15.56M |
| Operating Income | -27.72M | -24.98M | -7.70M | -13.01M | -11.59M |
| Income Before Tax | -25.91M | -24.39M | -7.12M | -12.56M | -11.00M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -25.91M | -24.39M | -7.12M | -12.56M | -11.00M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.91M | -24.39M | -7.12M | -12.56M | -11.00M |
| EBIT | -27.72M | -24.98M | -7.70M | -13.01M | -11.59M |
| EBITDA | -27.23M | -24.58M | -7.32M | -12.65M | -11.23M |
| EPS Basic | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 |
| Normalized Basic EPS | -0.35 | -0.33 | -0.10 | -0.24 | -0.22 |
| EPS Diluted | -0.57 | -0.53 | -0.16 | -0.38 | -0.35 |
| Normalized Diluted EPS | -0.35 | -0.33 | -0.10 | -0.24 | -0.22 |
| Average Basic Shares Outstanding | 45.71M | 45.64M | 44.51M | 33.09M | 31.84M |
| Average Diluted Shares Outstanding | 45.71M | 45.64M | 44.51M | 33.09M | 31.84M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |